Low-Dose Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Allogeneic Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Chronic Myelogenous Leukemia - Contacts and Locations

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

Low-Dose Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Allogeneic Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Chronic Myelogenous Leukemia

This study is ongoing, but not recruiting participants.

Study NCT00069992. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00069992

Locations


United States, Texas
	Dan L. Duncan Cancer Center at Baylor College of Medicine
	Houston, Texas, United States, 77030
	Methodist Hospital
	Houston, Texas, United States, 77030
	Texas Children's Hospital
	Houston, Texas, United States, 77030

Sponsors and Collaborators

Baylor College of Medicine

Investigators


Study Chair:	George Carrum, MD	Baylor College of Medicine